SCHEDULE 13D/A: Insider Sells Collplant Shares, Ownership Drops to 12.9%

Ami Sagy, a significant beneficial owner, has reduced his stake in Collplant Biotechnologies Ltd. by selling 140,000 ordinary shares, bringing his total ownership to 12.9%.

Summary

• Ami Sagy, a beneficial owner of Collplant Biotechnologies Ltd., filed an Amendment No. 4 to Schedule 13D to report changes in his ownership.
• The filing details the sale of 140,000 Ordinary Shares (represented by American Depositary Shares) by Ami Sagy during the period from October 16, 2025, through November 19, 2025.
• This sale has resulted in a material decrease in Ami Sagy's beneficial ownership since his last filing on November 5, 2019.
• Ami Sagy now beneficially owns 1,637,086 Ordinary Shares, which represents 12.9% of the company's outstanding shares.
• The percentage of ownership is based on 12,716,014 outstanding ordinary shares as of August 19, 2025.
• The shares were sold on the Nasdaq Capital Market at average prices ranging from $1.89 to $2.44 per share.
• Ami Sagy states he holds the Ordinary Shares for investment purposes and may acquire or sell additional shares in the future based on various factors.

Sentiment

Score: 3

Explanation: The filing reports a material decrease in beneficial ownership by a significant insider due to share sales, which typically generates negative sentiment among investors as it can signal a lack of confidence or a belief that the stock is fully valued.

Negatives

• Ami Sagy, a significant beneficial owner, sold 140,000 Ordinary Shares, indicating a reduction in his stake.
• His beneficial ownership has materially decreased from the level reported in his previous filing on November 5, 2019.
• The sales occurred at various price points between $1.89 and $2.44 per share, suggesting a willingness to divest at these valuations.

Risks

• The reporting person may, from time to time, acquire additional Ordinary Shares or sell existing Ordinary Shares, which could introduce volatility or impact the market price of the Issuer's securities.

Future Outlook

Ami Sagy holds the Ordinary Shares for investment purposes only and may, from time to time, based on various factors, acquire additional Ordinary Shares or sell Ordinary Shares, on the open market or in privately negotiated transactions. He does not have any definitive plans or proposals for extraordinary corporate transactions, changes in the board or management, material changes in capitalization or dividend policy, or other significant changes to the Issuer's business or corporate structure.

Industry Context

This filing primarily reflects an individual insider's investment activity rather than broader industry trends. Collplant Biotechnologies operates in the biotechnology sector, but the reported share sales by a beneficial owner do not provide specific insights into the industry's performance or outlook.

Legal Proceedings

• Ami Sagy has not been convicted in a criminal proceeding during the last five years.
• Ami Sagy was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws during the last five years.

Stakeholder Impact

• Shareholders: The sale by a significant beneficial owner could be perceived negatively by the market, potentially leading to downward pressure on the stock price as it may signal reduced insider confidence or a belief that the shares are adequately valued.
• Company Management: While not directly impacting daily operations, significant insider selling can raise questions among investors regarding management's alignment with major shareholders or the company's future prospects.

Next Steps

• Ami Sagy may acquire additional Ordinary Shares of the Issuer or sell Ordinary Shares, on the open market or in privately negotiated transactions, based on various factors.

Key Dates

Recommendation

The material reduction in beneficial ownership by a significant insider, Ami Sagy, through the sale of 140,000 shares, suggests a potential lack of confidence or a belief that the stock is fully valued at current levels. While the filing states the shares are held for investment purposes, the action of selling a substantial portion of a stake often signals a negative outlook from an informed party, prompting a 'sell' recommendation for investors to consider reducing their exposure.

Keywords

Collplant Biotechnologies, Ami Sagy, Schedule 13D, insider selling, beneficial ownership, ordinary shares, ADSs, biotechnology, SEC filing, stock sale